ClinicalTrials.gg
RecruitingNCT05899166Updated Apr 24, 2025

Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes

An interventional study of Ketogenic diet, food delivery and education and Standard diet, food delivery and education in Diabetes Mellitus, Type 1, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
5 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
525th of 1,242
52 · median 40
Started
2024
with 62 others
No phase
614 of 1,458
99 open now
Primary completion
2028-04
later than 189 of 256 live
Registered
1,216th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 525th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 63 that started in 2024, is one of 614 with no phase, reaches primary completion later than 189 of the 256 other live ones, and was the 1,216th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 5 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the effects of a ketogenic diet on the progression and control of type 1 diabetes in children with newly diagnosed diabetes. The main questions to answer are:

  • Does a ketogenic diet prolong the honeymoon period of type 1 diabetes?
  • Does a ketogenic diet improve diabetes control?
  • Is a ketogenic diet safe, acceptable and sustainable in children with newly diagnosed diabetes?
  • What are the microbiome, inflammatory and metabolic changes linking diet to β-cell function?

Participants will receive a combination of free meals, groceries, micronutrient supplements, and intensive diet and diabetes education for 9 months.

  • Diabetes care devices will be connected for cloud-based data collection.
  • Bi-weekly data downloads and remote check-ins will assess dietary intake, satisfaction with diet and study procedures, and possible safety concerns.
  • During four study visits held at at baseline, 1, 5, and 9 months, an intravenous catheter (IV) will be placed for collection of 5 blood samples before and up to 2 hours after a liquid test meal (protein shake) to assess insulin response. A stool sample will also be collected to assess microbiome changes.
  • Children and their caregivers may be invited to participate in a semi-structured interview, and online questionnaires to assess their experience with the diet and diabetes care, general well-being and quality of life.
  • Children and their caregivers may be invited to participate in a follow-up visit to evaluate long-term effects after 24 months.

Comparison will be made between a ketogenic vs standard diet.

Read the detailed description

Type I diabetes is caused by an autoimmune destruction of insulin producing β-cells in the pancreas, resulting in absolute insulin deficiency. In the first months after diagnosis, a small number of β-cells typically remain and, by producing insulin, significantly improve diabetes control and reduce disease burden.

Preliminary data suggest that this early disease stage entitled the "honeymoon period" might be extended by a ketogenic diet, which would provide a major therapeutic advantage and may reduce chronic disease burden.

To test the hypothesis that a ketogenic vs. standard diet will extend the honeymoon period and improve diabetes control in children, the researchers are conducting a study employing education and food deliveries of a ketogenic or standard diet to children and their families. Fifty-two children aged 5 to 12 years with newly diagnosed diabetes will participate. Children will be assigned by chance (randomized) to receive either a ketogenic or a standard diet for 9 months. Chances to be assigned to either diet are 50:50 like a coin flip, and 26 children will participate in each diet arm.

Participants will receive a combination of free meals, groceries, micronutrient supplements, and intensive diet and diabetes education throughout the 9 months. Continuous glucose monitoring (CGM) and diaries will be used for cloud-based data collection. Bi-weekly data downloads and remote check-ins will be performed to assess dietary intake, satisfaction with diet and study procedures, and possible safety concerns. Participants are instructed to measure blood ketone levels with their home ketone meter anytime blood glucose levels exceed a safety threshold and to call the study physician for persistent low glucose levels or ketones above diet specific safety thresholds.

Study visits are held at at baseline, 1, 5, and 9 months to collect height, weight, stool and blood samples for hormones, metabolites and inflammatory biomarkers. At each visit, an intravenous catheter (IV) will be placed to collect fasting blood samples, followed by a liquid test meal (protein shake) and collection of four additional blood samples from the IV over the course of two hours. Prior to each visit, participants will collect stool samples at home using provided kits. In addition, participants and their families may be invited to participate in a semi-structured interview, and online questionnaires to asses their food intake, experience with the diet, diabetes care burden and complications, and general well-being and quality of life. They may also be invited to participate in a follow-up visit to evaluate long-term effects after 24 months.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • carbohydrate reduced
  • low-carb
  • diabetes
  • keto
04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 5 to 12 years.
  • Within 3 month of diabetes diagnosis.
  • Insulin adjusted ≤9 if enrolled ≥ 2 months pat diagnosis.
  • Type 1 diabetes confirmed by immediate insulin requirement and any 2 of the following criteria: autoimmunity marker [glutamate decarboxylase-65, islet-antigen-2, zinc transporter-8, insulin [prior to first insulin dose]; age under 10 years, \<95th percentile.
  • Family committed and able to participate in study education and implement dietary intervention.

Exclusion criteria

Exclusion Criteria:

  • Dietary needs or habits incompatible with the study meal plans, (e.g., vegan, major food intolerances/allergies, ketogenic).
  • Eating disorders as assessed by Chede-Q8.
  • Major medical illness or use of medications other than insulin that could interfere with metabolic or glycemic variables.
  • Major psychiatric illness.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    ketogenic diet

    The diet will be high in protein and healthy fats and comprise meat, fish, fibrous vegetables, nuts, dairy, and berries. Macronutrient composition will be \~ 5% carbohydrate, 20% protein, 70% fat. Participants will receive a daily multi-vitamin, magnesium supplement, and supplemental salt (bouillon cubes) to ascertain micronutrient sufficiency and help with transition to the diet.

    Other: Ketogenic diet, food delivery and education

  • Active comparator
    standard diet

    The diet will be consistent with prevailing dietary guidelines and recommendations and contain meat, fish, grains, vegetables, fruit and dairy. At least 50% of grain-based products will be whole grains. Meats will be primarily lean, and dairy products will be fat-free or low-fat. Macronutrient composition will be \~50% carbohydrate (\<10% added sugars), 20% protein, 30% fat. Participants will receive a daily multi-vitamin supplement to ascertain micronutrient sufficiency.

    Other: Standard diet, food delivery and education

Interventions

  • OtherKetogenic diet, food delivery and education

    Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.

  • OtherStandard diet, food delivery and education

    Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.

06

What researchers measure

Primary outcomes

  1. Decline in Beta-cell Function

    Change in C-peptide 2-h area under the curve after a mixed-meal tolerance test (ΔCP).

    Time frame: Change over 1, 5, and 9 months, corrected for baseline

Secondary outcomes

  1. Time in Range (TIR) 70-180 mg/dl

    From continuous glucose monitoring (CGM) - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  2. Duration of Clinical Diabetes Remission

    Calculated based on percent children with insulin dose corrected HbA1c (IDAA1c) \<9.

    Time frame: 1, 5, 9, and optional at 24 months

  3. Time in low Range (TIR) <70 mg/dl

    From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  4. Time in very low Range (TIR) <55 mg/dl

    From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  5. Time in high Range (TIR) >180 mg/dl

    From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  6. Time in very high Range (TIR) >250 mg/dl

    From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  7. Average Blood Glucose

    From CGM - will be computed throughout study participation in 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  8. Coefficient of Glycemic Variation (CV)

    From CGM - will be computed by dividing glucose standard deviation by glucose average throughout study participation in 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  9. Mean Amplitude of Glycemic Excursions (MAGE)

    From CGM - will be computed using published formula throughout study participation in 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  10. Total Daily Insulin Dose

    From insulin administration device uploads - will be computed in units per kg throughout study participation in 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  11. HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)

    Calculated from fasting blood draw \[fasting insulin (µU/ml) × fasting plasma glucose (mg/dl)\]/405.

    Time frame: 1, 5, 9, and optional at 24 months

  12. BMI

    Weight divided by height squared.

    Time frame: 1, 5, 9, and optional at 24 months

  13. Lipid panel

    Fasting blood - total, LDL and HDL cholesterol, and triglycerides.

    Time frame: 1, 5, 9, and optional at 24 months

  14. HDL to Triglyceride Ratio

    Fasting blood

    Time frame: 1, 5, 9, and optional at 24 months

  15. Lipoprotein Subfractions

    Fasting blood

    Time frame: 1, 5, 9, and optional at 24 months

  16. Inflammasome, targeted

    Interleukins 1β, 17, 23, 6, 10; high sensitivity c-reactive protein; tumor necrosis factor α, interferon gamma

    Time frame: 1, 5, 9, and optional at 24 months

  17. Microbiome, targeted and untargeted

    Extraction and sequencing will be performed by Qiagen PowerSoil DNA extraction using Qiagen's DNeasy 96 PowerSoil Pro QIAcube HT Kit (480), followed by whole genome sequencing (WGS) using a miniaturized version of the NEBNext Ultra FS II method.

    Time frame: 1, 5, 9, and optional at 24 months

  18. Metabolome, targeted and untargeted

    Blood samples will be processed using liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR). The LC-MS analyses will be carried out on a Sciex triple quadrupole mass spectrometer couple to an Exion ultra-performance LC system. The targeted analysis will utilize the Biocrates Q500 targeted metabolomics assay which quantifies more than 500 metabolites over 26 chemical classes (Biocrates Inc., Innsbruck, Austria). Data processing to yield metabolite concentrations in micromolar units will utilize the Biocrates MetIDQ software. The NMR data will be acquired on a Bruker Avance NEO 700 MHz NMR equipped with a TCI cryoprobe and a SampleXPress automatic sample changer. The data will be processed using the Chenomx NMR Processor and Profiler packages (Chenomx, Edmonton, CA) to yield quantitative data in millimolar units.

    Time frame: 1, 5, 9, and optional at 24 months

  19. Problem Areas in Diabetes (PAID-Ped) - child

    Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate greater burden.

    Time frame: 1, 5, 9, and optional at 24 months

  20. Problem Areas in Diabetes (PAID-PR) - parent

    Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate greater burden.

    Time frame: 1, 5, 9, and optional at 24 months

  21. Pediatric Quality of Life (PEDSQL) General Module - parent

    Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate better quality of life.

    Time frame: 1, 5, 9, and optional at 24 months

  22. Pediatric Quality of Life (PEDSQL) General Module - child

    Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate better quality of life.

    Time frame: 1, 5, 9, and optional at 24 months

  23. Pediatric Quality of Life (PEDSQL) Diabetes Module - parent

    Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate less problems.

    Time frame: 1, 5, 9, and optional at 24 months

  24. Pediatric Quality of Life (PEDSQL) Diabetes Module - child

    Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate less problems.

    Time frame: 1, 5, 9, and optional at 24 months

  25. Child Eating Disorder Examination Questionnaire (ChEDE-Q8)

    Validated questionnaire, scored according to published standards. Scores range 0-42, higher scores are worse.

    Time frame: 1, 5, 9, and optional at 24 months

  26. Perceptions on Diet Management of Diabetes

    Questionnaire to assess participants' and caregivers' perceptions of the influence of the diet on their diabetes management.

    Time frame: 1, 5, 9, and optional at 24 months

  27. Qualitative patient perspectives, interview - parent

    Interviews will be held with children and caregivers separately after implementation and completion of the intervention.

    Time frame: optional at 9 months

  28. Qualitative patient perspectives, interview - child

    Interviews will be held with children and caregivers separately after implementation and completion of the intervention.

    Time frame: optional at 9 months

Other outcomes

  1. Time in tight Range (TIR) 70-140 mg/dl

    From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  2. Time above tight Range (TIR) >140 mg/dl

    From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.

    Time frame: Over 9 months and optional at 24 months

  3. BOHB (beta-hydroxybutyrate), fasting blood concentration

    Obtained at daily increasing to weekly intervals as effect modifier of beta-cell function.

    Time frame: Over 9 months and optional at 24 months

  4. Growth

    Safety Measure - Height standard deviation score will be calculated from serial height measurements obtained during study visits using CDC age and sex specific references.

    Time frame: 1, 5, 9, and optional at 24 months

  5. Growth velocity

    Safety Measure - Growth velocity will be calculated from serial height measurements obtained during study visits.

    Time frame: 1, 5, 9, and optional at 24 months

  6. Weigh-gain

    Safety Measure - Weight SDS and gain will be calculated from serial weight measures obtained during study visits with calibrated scale.

    Time frame: 1, 5, 9, and optional at 24 months

  7. Confirmed Ketoacidosis

    Safety Measure - Defined by elevated BOHB, blood pH \<7.3 and serum bicarbonate \<15. Rates will be computed as total number of events divided by total patient years of follow-up.

    Time frame: Over 9 months and optional at 24 months

  8. Severe Hypoglycemia

    Safety Measure - Defined as blood glucose \< 55 mg/dl and requiring glucagon or resulting in seizure or coma. Rates will be computed as total number of events divided by total patient years of follow-up.

    Time frame: Over 9 months and optional at 24 months

  9. Diabetes Related Emergency Visits

    Safety Measure - Rates will be computed as total number of events divided by total patient years of follow-up.

    Time frame: Over 9 months and optional at 24 months

  10. Diabetes Related Hospitalizations

    Safety Measure - Rates will be computed as total number of events divided by total patient years of follow-up.

    Time frame: Over 9 months and optional at 24 months

  11. Study termination for disordered eating

    Safety Measure - ChEDE-Q8 diagnostic score with clinical confirmation. Total number of events.

    Time frame: Over 9 months

  12. Study termination for growth deceleration

    Safety Measure - Undesired weight loss or significant deceleration in longitudinal growth may warrant termination of study participation. Total number of events will be computed.

    Time frame: Over 9 months

  13. Study termination for dyslipidemia

    Safety Measure - LDL \>200 mg/dl will trigger review of additional risk factors and may prompt diet modification to lower intake of saturated fats. If persistent, study participation may be terminated. Total number of events will be computed.

    Time frame: Over 9 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lennerz BS, Koutnik AP, Azova S, Wolfsdorf JI, Ludwig DS. Carbohydrate restriction for diabetes: rediscovering centuries-old wisdom. J Clin Invest. 2021 Jan 4;131(1):e142246. doi: 10.1172/JCI142246. PubMed 33393511 ↗
  • Lennerz BS, Barton A, Bernstein RK, Dikeman RD, Diulus C, Hallberg S, Rhodes ET, Ebbeling CB, Westman EC, Yancy WS Jr, Ludwig DS. Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet. Pediatrics. 2018 Jun;141(6):e20173349. doi: 10.1542/peds.2017-3349. Epub 2018 May 7. PubMed 29735574 ↗

Individual participant data

Plan to share: Yes — Upon publication, de-identified raw data for each original article will be uploaded to the appropriate an NIH maintained repository.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Study protocol and statistical analysis plan will be shared prior to enrollment of the first participant. De-identified data will be shared upon manuscript publication.

Access criteria: Data will be downloadable.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Apr 2028, 46 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 46 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Jun 12, 2023
StartActual
May 31, 2024
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2029
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05899166
Responsible party
Belinda Lennerz (Assistant Professor in Pediatrics, Boston Children's Hospital) — Principal investigator
First posted
Jun 12, 2023
Start date
May 31, 2024
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Apr 24, 2025

Study contacts

Belinda Lennerz, MD PhD
Contact
belinda.lennerz@childrens.harvard.edu
857-218-3896
Belinda Lennerz
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion